RxDoctor Payments DataLook up a doctor →

Sean Bodin, PA

Medical · Fredericksburg, VANPI 1841799939

Payments from drug & device makers

$8,441in general payments, 2019–2025

Across 653 payments — averaging $12.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$805
  • Otsuka America Pharmaceutical, Inc.$776
  • Novo Nordisk$642
  • Lilly USA, LLC$633
  • Pfizer$482
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,36899%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,441 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$63,208
Medicare patients
247
Services billed
1,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$44,227
JardianceEmpagliflozin38$43,021
FarxigaDapagliflozin Propanediol42$34,376
OzempicSemaglutide14$31,038
RexultiBrexpiprazole12$20,216
LinzessLinaclotide20$18,959
JanuviaSitagliptin Phosphate12$18,804
JanumetSitagliptin Phos/Metformin Hcl14$11,081
XareltoRivaroxaban14$10,264
MyrbetriqMirabegron11$4,853
Atorvastatin Calcium315$2,802
Levothyroxine Sodium164$2,263
Rosuvastatin Calcium141$1,784
Telmisartan40$1,516
Duloxetine Hcl55$1,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$482$44,22728 claims
Boehringer IngelheimJardiance$81$43,02138 claims
AstraZenecaFarxiga$805$34,37642 claims
Novo NordiskOzempic$642$31,03814 claims
MerckJanuvia, Janumet$29$29,88426 claims
Otsuka America Pharmaceutical, Inc.Rexulti$776$20,21612 claims
AbbVieLinzess$1,449$18,95920 claims
Johnson & JohnsonXarelto$27$10,26414 claims
Astellas Pharma US IncMyrbetriq$234$4,85311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.

Other medical in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →